Vaccine Development and Production Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Vaccine Development and Production. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Vaccine Development and Production Indian Medical PG Question 1: Which of the following vaccines is currently used as a live attenuated vaccine in routine immunization programs?
- A. Measles (Correct Answer)
- B. Inactivated Polio Vaccine (IPV)
- C. Smallpox
- D. Cholera
Vaccine Development and Production Explanation: ***Measles***- The **measles vaccine** is a **live attenuated vaccine** that induces a strong and long-lasting immune response against the measles virus.- It is a core component of routine childhood immunization programs globally, often given as part of the **MMR (Measles, Mumps, Rubella)** vaccine.*Inactivated Polio Vaccine (IPV)*- **IPV** is an **inactivated (killed) vaccine** that contains polioviruses grown in culture and then chemically inactivated. [1]- It is administered via injection and produces systemic immunity without the risk of vaccine-associated paralytic poliomyelitis (VAPP).*Smallpox*- The **smallpox vaccine** contained a **live vaccinia virus**, which is related to smallpox but much safer.- While it was a live vaccine, smallpox has been eradicated, and routine vaccination is no longer practiced except for specific laboratory personnel.*Cholera*- Most commonly used cholera vaccines are either **inactivated (killed whole-cell)** vaccines or **live attenuated oral vaccines**.- While a live attenuated oral cholera vaccine exists, it is not part of routine childhood immunization programs in most countries, but rather used in specific outbreak settings or for travelers.
Vaccine Development and Production Indian Medical PG Question 2: The quality control agent for sterilization in an autoclave is:
- A. Bacillus globigii
- B. Bacillus subtilis
- C. Bacillus pumilus
- D. Bacillus stearothermophilus (Correct Answer)
Vaccine Development and Production Explanation: ***Bacillus stearothermophilus***
- **_Bacillus stearothermophilus_** spores are used as **biological indicators** for **autoclave sterilization** (moist heat) due to their high resistance to heat.
- Their destruction indicates that the sterilization cycle has been effective in achieving sterility.
*Bacillus subtilis*
- **_Bacillus subtilis_** spores are typically used as biological indicators for **ethylene oxide sterilization**, not autoclaving.
- While robust, they are not the standard indicator for **moist heat sterilization** due to their lower resistance compared to _B. stearothermophilus_.
*Bacillus pumilus*
- **_Bacillus pumilus_** spores are used as biological indicators primarily for **radiation sterilization** processes.
- They are not the standard **biological indicator** for **autoclave efficacy**.
*Bacillus globigii*
- **_Bacillus globigii_** (now known as _Bacillus atrophaeus_) spores are used as biological indicators for **dry heat sterilization**.
- They are not the appropriate indicator for **moist heat sterilization** using an autoclave.
Vaccine Development and Production Indian Medical PG Question 3: All of the following statements about MMR vaccine are true EXCEPT:
- A. All live vaccines without exception are contraindicated in pregnant women (Correct Answer)
- B. MMR is a live vaccine
- C. Adverse events from MMR vaccine include fever (usually 6-12 days following vaccination), rash in 5% of vaccinated persons, arthralgia, aseptic meningitis, lymphadenopathy
- D. Evidence shows that aseptic meningitis is associated with all mumps vaccine strains except the Jeryl Lynn strain
Vaccine Development and Production Explanation: ***Correct Answer: All live vaccines without exception are contraindicated in pregnant women***
- This statement is **FALSE**, making it the correct answer to this EXCEPT question
- While **most live vaccines are contraindicated in pregnancy** (including MMR), the word **"without exception"** makes this statement incorrect
- **Exceptions exist**: Yellow fever vaccine may be administered during pregnancy if travel to endemic areas is unavoidable and the risk of disease outweighs the theoretical vaccine risk
- The absolute nature of this statement contradicts clinical guidelines that recognize situational exceptions
*True Statement - MMR is a live vaccine*
- **MMR vaccine** contains **live-attenuated viruses** of measles, mumps, and rubella
- This live-attenuated nature produces robust, long-lasting immunity
- Being a live vaccine necessitates contraindications in immunocompromised patients and pregnant women
*True Statement - Adverse events from MMR vaccine*
- **Fever** typically occurs **6-12 days post-vaccination** (not immediately), reflecting viral replication
- **Rash** occurs in approximately **5% of vaccinees**
- Other documented adverse events include **arthralgia** (especially in adult women), **aseptic meningitis** (rare), and **lymphadenopathy**
- These adverse events are far less severe than complications from natural measles, mumps, or rubella infection
*True Statement - Aseptic meningitis and vaccine strains*
- **Urabe** and **Leningrad-Zagreb** mumps vaccine strains have been associated with higher rates of vaccine-associated **aseptic meningitis** (approximately 1 in 100,000 to 1 in 1 million doses)
- The **Jeryl Lynn strain** (used in the United States and many other countries) has **negligible or no association** with aseptic meningitis
- This safety profile makes the Jeryl Lynn strain the preferred mumps component in MMR vaccines
Vaccine Development and Production Indian Medical PG Question 4: Which of the following is not a polysaccharide vaccine?
- A. Pneumococcal vaccine
- B. Meningococcal vaccine
- C. H. Influenzae B vaccine
- D. Hepatitis B vaccine (Correct Answer)
Vaccine Development and Production Explanation: ***Hepatitis B vaccine (recombinant protein vaccine)***
- This is a **recombinant protein vaccine** which contains **HBsAg** (Hepatitis B surface antigen) produced in yeast.
- As it uses a protein antigen, it is not a polysaccharide vaccine.
*Pneumococcal vaccine (includes polysaccharide forms)*
- There are two types: **Pneumococcal Polysaccharide Vaccine (PPSV23)** which is a pure polysaccharide vaccine, and **Pneumococcal Conjugate Vaccine (PCV13, PCV15, PCV20)** which contains polysaccharides conjugated to a protein carrier.
- Both types utilize **polysaccharide antigens** from *Streptococcus pneumoniae* to elicit an immune response.
*Meningococcal vaccine (includes polysaccharide forms)*
- Similar to pneumococcal vaccines, there are **meningococcal polysaccharide vaccines (MPSV4)** and **meningococcal conjugate vaccines (MCV4)**.
- These vaccines use **polysaccharides** from the capsule of *Neisseria meningitidis* as their immunogenic component, either alone or conjugated.
*H. Influenza B vaccine (conjugate vaccine derived from polysaccharides)*
- This is a **conjugate vaccine** that uses a **polysaccharide capsule antigen** from *Haemophilus influenzae type B* (Hib) chemically linked to a protein carrier.
- Conjugation improves immunogenicity, especially in infants, by converting the T-independent polysaccharide antigen into a T-dependent one.
Vaccine Development and Production Indian Medical PG Question 5: Which route is the H1N1 live vaccine administered by?
- A. Intramuscular
- B. Intranasal (Correct Answer)
- C. Oral
- D. Subcutaneous
Vaccine Development and Production Explanation: ***Intranasal***
- The **live attenuated influenza vaccine (LAIV)**, often referred to as the "nasal spray flu vaccine," is administered intranasally.
- This route allows the vaccine to replicate in the **nasal passages**, mimicking natural infection and stimulating a localized immune response.
*Intramuscular*
- The **inactivated influenza vaccine (IIV)**, or the "flu shot," is administered intramuscularly.
- This route delivers the vaccine into the **muscle tissue** to stimulate a systemic immune response without local replication.
*Subcutaneous*
- Subcutaneous administration is used for some vaccines, but it is **not the standard route** for either live or inactivated influenza vaccines.
- This route delivers the vaccine into the **fatty tissue** just under the skin.
*Oral*
- Oral administration is typically used for live vaccines that need to replicate in the **gastrointestinal tract**, such as the rotavirus vaccine.
- It is **not an appropriate route** for influenza vaccines as the virus needs to stimulate respiratory immunity.
Vaccine Development and Production Indian Medical PG Question 6: All of the following are recognized adverse effects of DPT vaccine:
- A. Seizures
- B. Abscess
- C. Encephalopathy
- D. Fever (Correct Answer)
Vaccine Development and Production Explanation: ***Fever***
- **Fever** is the most common and expected adverse effect after DPT vaccination due to the body's normal immune response to the vaccine components.
- It's usually mild and self-limiting, indicating the immune system is building protection.
- Occurs in 30-50% of recipients and is considered a typical reaction rather than a complication.
*Seizures*
- While rare, **seizures** (febrile or afebrile) have been reported as adverse events following DPT vaccination.
- Febrile seizures are more common and usually brief without long-term neurological damage.
- The risk is very low (approximately 1 in 14,000 doses), and benefits far outweigh this potential risk.
*Abscess*
- An **abscess** at the injection site can occur as a local complication, though uncommon.
- May result from improper injection technique, contamination, or local tissue reaction.
- Requires medical attention and possible drainage.
*Encephalopathy*
- **Encephalopathy** (serious brain injury) was recognized as an extremely rare severe adverse event associated with the **whole-cell pertussis component** of older DPT vaccines.
- Risk estimated at less than 1 in 1 million doses.
- Modern DTaP (acellular pertussis) vaccines have largely replaced whole-cell DPT to significantly reduce this risk.
Vaccine Development and Production Indian Medical PG Question 7: Congenital passive immunity is INADEQUATE in -
- A. Measles
- B. Mumps
- C. RSV (Respiratory Syncytial Virus)
- D. Pertussis (Correct Answer)
Vaccine Development and Production Explanation: ***Pertussis***
- **Congenital passive immunity** against *Bordetella pertussis* is **most inadequate** among the listed infections.
- **Minimal transplacental transfer** of protective IgG antibodies occurs, and maternal antibodies decline rapidly in infants.
- Newborns have **virtually no protection** from maternal antibodies, making them highly susceptible to severe whooping cough.
- This is why **early vaccination at 6 weeks** is critical, unlike measles which can wait until 9-12 months.
*Measles*
- Maternal antibodies provide **excellent passive immunity** protecting infants for **6-9 months**.
- This robust protection is why measles vaccination is delayed until 9-12 months of age.
- Represents the **gold standard** of effective maternal antibody transfer.
*Mumps*
- Maternal antibodies provide **good passive immunity** in early infancy.
- Mumps in young infants is rare due to this maternal protection.
*RSV (Respiratory Syncytial Virus)*
- Maternal antibodies provide **limited but present** passive immunity.
- Unlike pertussis where protection is nearly absent, RSV maternal antibodies can **reduce severity** of illness.
- However, RSV remains a major cause of bronchiolitis in infants despite this partial protection.
- The key difference: RSV has **some** maternal protection (inadequate but present), whereas pertussis has **almost none** (most inadequate).
Vaccine Development and Production Indian Medical PG Question 8: An 18-year-old girl is brought to the emergency department because of a 1-day history of severe headache with photophobia and diffuse myalgias. She is a college student and lives in a dormitory in a large urban area. She has not traveled recently. On arrival, she is lethargic. Her temperature is 39.3°C (102.7°F), pulse is 120/min, and blood pressure is 88/58 mm Hg. Examination shows scattered petechiae and ecchymoses on the trunk and lower extremities. There is decreased range of motion of the neck. Cerebrospinal fluid analysis shows a cell count of 1,600/μL (80% neutrophils) and a lactate concentration of 5.1 mmol/L. Which of the following is most likely to have prevented this patient's condition?
- A. Intravenous vancomycin
- B. Polysaccharide conjugate vaccine (Correct Answer)
- C. Erythromycin therapy
- D. Doxycycline therapy
- E. Toxoid vaccine
Vaccine Development and Production Explanation: ***Polysaccharide conjugate vaccine***
- This patient presents with symptoms highly suggestive of **bacterial meningitis** and **septic shock**, likely caused by *Neisseria meningitidis*, given the petechiae, ecchymoses, and rapid deterioration.
- A **meningococcal conjugate vaccine** would have provided protection against most common serogroups of *N. meningitidis* (A, C, W-135, Y) and is strongly recommended for college students living in dormitories due to increased risk of transmission.
*Intravenous vancomycin*
- This is an **acute treatment** for bacterial meningitis, specifically active against *Streptococcus pneumoniae* and some resistant strains.
- It would not have **prevented** the condition; preventative measures are typically vaccines or prophylactic antibiotics.
*Erythromycin therapy*
- Erythromycin is an antibiotic used for various bacterial infections, including atypical pneumonia and some skin infections.
- It is **not the primary prophylactic agent** for meningococcal disease and would not have prevented this specific condition.
*Doxycycline therapy*
- Doxycycline is a broad-spectrum antibiotic used for a range of infections, including tick-borne diseases and certain respiratory infections.
- It is **not indicated for the prevention** of meningococcal meningitis.
*Toxoid vaccine*
- **Toxoid vaccines** protect against diseases caused by bacterial toxins, such as tetanus and diphtheria.
- *Neisseria meningitidis* causes disease primarily through direct invasion and immune response to its capsular polysaccharides, not primarily exotoxins, so a toxoid vaccine would not be effective here.
Vaccine Development and Production Indian Medical PG Question 9: All of the following regarding rotavirus vaccine are correct except?
- A. Oral vaccine
- B. Cannot be given after 6 months of age (Correct Answer)
- C. Available as monovalent and pentavalent
- D. Live vaccine
Vaccine Development and Production Explanation: ***Cannot be given after 6 months of age***
- This statement is **INCORRECT**, making it the correct answer for this "EXCEPT" question.
- The rotavirus vaccine CAN be given after 6 months of age when completing the vaccination series.
- **Rotarix (RV1)**: First dose at 6-14 weeks, second dose by **8 months of age**
- **RotaTeq (RV5)**: First dose at 6-14 weeks, complete 3-dose series by **8 months of age**
- The key restriction is that the **first dose must be given between 6 to 14 weeks 6 days** (not after 15 weeks due to increased intussusception risk), but subsequent doses can be given after 6 months to complete the series.
*Oral vaccine*
- **CORRECT statement**: The rotavirus vaccine is an **oral vaccine**, administered as drops into the infant's mouth.
- This route avoids injections and improves compliance in pediatric immunization.
*Available as monovalent and pentavalent*
- **CORRECT statement**: Two types are available:
- **Rotarix (RV1)**: Monovalent vaccine targeting G1P[8] strain
- **RotaTeq (RV5)**: Pentavalent vaccine targeting G1, G2, G3, G4, and P[8] strains
- Both are highly effective in preventing severe rotavirus gastroenteritis.
*Live vaccine*
- **CORRECT statement**: Both rotavirus vaccines contain **live, attenuated viruses**.
- This stimulates robust mucosal and systemic immunity against rotavirus infection.
- Contraindicated in severe combined immunodeficiency (SCID) and after intussusception.
Vaccine Development and Production Indian Medical PG Question 10: A young male came to the hospital with a clean-cut wound without any bleeding. The patient received a full course of tetanus vaccination 10 years ago. What is the best management for this patient?
- A. Single-dose tetanus toxoid (Correct Answer)
- B. Human tetanus immunoglobulin only
- C. Human tetanus immunoglobulin and a full course of vaccine
- D. No treatment required
Vaccine Development and Production Explanation: ***Single-dose tetanus toxoid***
- For a **clean-cut wound** in a patient who completed a **primary tetanus vaccination series** and received their last dose more than 5 years ago but less than 10 years ago, a **single booster dose** of tetanus toxoid is recommended. [1]
- A booster ensures continued protection, as vaccine-induced immunity wanes over time, but the prior full course provides a robust anamnestic response with a single dose.
*Human tetanus immunoglobulin and a full course of vaccine*
- This regimen (tetanus immunoglobulin + vaccine) is typically reserved for patients with **unvaccinated status**, an **unknown vaccination history**, or a **severely contaminated wound** (e.g., rusty nail, soil contamination) who have not been fully vaccinated.
- The patient had a **clean-cut wound** and completed a full course of vaccination 10 years ago, making immunoglobulin unnecessary and a full course of vaccine excessive.
*Human tetanus immunoglobulin only*
- Administering **tetanus immunoglobulin alone** is appropriate for immediate, passive immunity in situations where a patient is unvaccinated or has an unknown vaccination status and has a significant risk of tetanus from a contaminated wound. [2]
- This patient has a clean wound and a history of full vaccination, so a booster is sufficient to stimulate active immunity.
*No treatment required*
- While the patient was fully vaccinated 10 years ago, the protection from tetanus vaccination can **wane over time**, especially after 5-10 years.
- A **booster dose** is crucial to maintain adequate protection against tetanus, even for a clean wound, given the 10-year interval since the last dose.
More Vaccine Development and Production Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
